Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.

abstract：:We report the clinical features and outcome of 22 TLS-ERG+ leukemia patients (20 AML and 2 B-ALL). TLS-ERG was tightly associated with extramedullary disease (EMD), complex chromosome abnormalities, and high risk gene mutations including IKZF1, WT1, TET2, NOTCH2, and PHF6. The 6-month leukemia free survival (LFS) with...

journal_title：Leukemia & lymphoma

authors： Pan J,Zhang Y,Zhao YL,Yang JF,Zhang JP,Liu HX,Wu T,Tong CR

更新日期：2017-07-01 00:00:00

abstract：:High dose cytosine arabinoside (ARA-C) has produced long term relapse free survival in 26% to 49% of patients when used as consolidation therapy of acute non-lymphocytic leukemia (ANLL) in first remission. However, the optimal consolidation regimen has not been defined. In this pilot study we attempted to confirm and ...

journal_title：Leukemia & lymphoma

authors： Stein RS,Greer JP,Flexner JM,Goodman S,Wolff SN

更新日期：1996-09-01 00:00:00

abstract：:The patient granulocyte-colony stimulating factor (G-CSF) response is represented by the leukocyte peak in the blood induced by a single dose of G-CSF after chemotherapy, and is correlated with subsequent neutropenic infection risk. General patterns for a meaningful risk group stratification, have not yet been determi...

journal_title：Leukemia & lymphoma

authors： Straka C,Salwender H,Schnabel B,Sandherr M,Wandt H,Hübel K,Scheid C,Metzner B,Hentrich M,Franke D,Weidenegger G,Freund M,Sezer O,Einsele H,Hinke A,Emmerich B

更新日期：2015-02-01 00:00:00

abstract：:Human herpes virus type 6 can reactivate in patients after allogeneic stem cell transplantation and has been associated with serious sequelae such as delayed engraftment and an increased risk of developing acute graft-versus-host disease (GVHD). This study investigated human herpes virus type 6 (HHV-6) reactivation wi...

journal_title：Leukemia & lymphoma

authors： Cirrone F,Ippoliti C,Wang H,Zhou XK,Gergis U,Mayer S,Shore T,van Besien K

更新日期：2016-11-01 00:00:00

abstract：:We describe the patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for the initial staging of patients with newly diagnosed grade 1-2 follicular lymphoma (FL) and its potential impact on treatment. Data were obtained from the National Comprehensive Cancer Network Non-Hodgkin Lymphoma...

journal_title：Leukemia & lymphoma

authors： Abou-Nassar KE,Vanderplas A,Friedberg JW,Abel GA,Niland J,Rodriguez MA,Czuczman MS,Millenson M,Crosby A,Gordon LI,Zelenetz AD,Kaminski M,Lacasce AS

更新日期：2013-10-01 00:00:00

abstract：:The proteasome inhibitor carfilzomib is highly effective in the treatment of multiple myeloma. It irreversibly binds the chymotrypsin-like active site in the β5 subunit of the 20S proteasome. Despite impressive response rates when carfilzomib is used in combination with immunomodulatory agents in newly diagnosed multi...

journal_title：Leukemia & lymphoma

authors： Manasanch EE,de Larrea CF,Zingone A,Steinberg SM,Kwok M,Tageja N,Bhutani M,Kazandjian D,Roschewski M,Wu P,Carter G,Zuchlinski D,Mulquin M,Lamping L,Costello R,Burton D,Gil LA,Figg WD,Maric I,Calvo KR,Yuan C,Stet

更新日期：2017-03-01 00:00:00

abstract：:Primary myelosarcomas, also called leukemia cutis, granulocytic sarcomas or chloromas, are rare extramedullary manifestations of acute myeloid leukemia (AML) which precede bone marrow involvement. Skin infiltration was the most frequent localization associated with a myelomonocytic differentiation. Although first remi...

journal_title：Leukemia & lymphoma

authors： Reinhardt D,Creutzig U

更新日期：2002-03-01 00:00:00

abstract：:We describe a patient with natural killer (NK)/T cell lymphoma who relapsed after autologous peripheral blood stem cell transplantation (auto-PBSCT) and was successfully treated with Escherichia coli (E. coli) and Erwinia L-asparaginase. A 38-year-old male patient with ulcerated tumor at the left thigh was diagnosed a...

journal_title：Leukemia & lymphoma

authors： Matsumoto Y,Nomura K,Kanda-Akano Y,Fujita Y,Nakao M,Ueda K,Horiike S,Yokota S,Kusuzaki K,Kitoh T,Watanabe A,Taniwaki M

更新日期：2003-05-01 00:00:00

abstract：:CXCR4 directs chronic lymphocytic leukemia (CLL) trafficking within protective tissue niches, and targeting CXCR4 with plerixafor may enhance drug sensitivity. We performed a phase 1 dose escalation study of plerixafor (NCT00694590) with rituximab in 24 patients with relapsed/refractory CLL. Patients received rituxima...

journal_title：Leukemia & lymphoma

authors： Andritsos LA,Byrd JC,Cheverton P,Wu J,Sivina M,Kipps TJ,Burger JA

更新日期：2019-12-01 00:00:00

abstract：:Lenalidomide is a backbone agent in the treatment of multiple myeloma, but dose adjustment is required for those with renal impairment (RI). We evaluated the pharmacokinetics (PK) and safety of lenalidomide and dexamethasone as frontline pre-transplant induction, with doses adjusted at start of each cycle based on cre...

journal_title：Leukemia & lymphoma

authors： Chen CI,Cao Y,Trudel S,Reece DE,Kukreti V,Tiedemann R,Prica A,Paul H,Le LW,Levina O,Kakar S,Lau A,Chen H,Chen E

更新日期：2020-08-01 00:00:00

abstract：:The age-adjusted incidence of Hodgkin's lymphoma (HL) is markedly higher in Saudi Arabia than in the USA, and accounts for 10.5% of all neoplasias in children aged 15 years or older in Saudi Arabia. Epstein-Barr virus (EBV) infection has been suspected to cause high HL incidence in developing countries. To investigate...

journal_title：Leukemia & lymphoma

authors： Al-Kuraya K,Narayanappa R,Al-Dayel F,El-Solh H,Ezzat A,Ismail H,Belgaumi A,Bavi P,Atizado V,Sauter G,Simon R

更新日期：2006-04-01 00:00:00

abstract：:Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, an...

journal_title：Leukemia & lymphoma

authors： Sidiqi MH,Gertz MA

更新日期：2019-02-01 00:00:00

abstract：:Although current immunochemotherapy has increased the therapeutic efficacy in diffuse large B-cell lymphoma (DLBCL), there are still some patients who present unfavorable outcomes. Novel effective treatment strategies are needed to improve the prognosis of DLBCL. In this review, we discussed the functional mechanisms ...

journal_title：Leukemia & lymphoma

authors： Wang M,Fang X,Wang X

更新日期：2020-04-01 00:00:00

abstract：:Data from the large, prospective, multinational, phase 3b JUMP study were analyzed to identify factors predictive of spleen and symptom responses in myelofibrosis patients receiving ruxolitinib. Factors associated with higher spleen response rates included International Prognostic Scoring System (IPSS) low/intermediat...

journal_title：Leukemia & lymphoma

authors： Gupta V,Griesshammer M,Martino B,Foltz L,Tavares R,Al-Ali HK,Giraldo P,Guglielmelli P,Lomaia E,Bouard C,Paley C,Tiwari R,Zor E,Raanani P

更新日期：2020-11-19 00:00:00

abstract：:In a prospective multicenter study 68 out of 158 patients with HIV infection and malignant lymphoma were assigned to a risk-adapted induction therapy using the following algorithm: High-risk patients fulfilled 2 of 3 criteria: T4 lymphocytes <50/microL; WHO activity index 3 or 4; pre-existing AIDS-defining opportunist...

journal_title：Leukemia & lymphoma

authors： Weiss R,Huhn D,Mitrou P,Nerl C,Schürmann D,Scheidegger C,Knauf W,Trenn G,Kronawitter U,Van Lunzen J,Arastéh K,Herbst H

更新日期：1998-03-01 00:00:00

abstract：:Preliminary results indicate that inhibitors of the nuclear enzyme topoisomerase (topo) I, such as topotecan, may be active in non-Hodgkin's lymphoma (NHL). Pre-clinical studies have shown sequential administration of a topo I and II inhibitor has supra-additive anti-tumor effects in some model systems, and that great...

journal_title：Leukemia & lymphoma

authors： Crump M,Couban S,Meyer R,Rudinskas L,Zanke B,Gluck S,Maksymiuk A,Hoskins P,Matthews S,Eisenhauer E

更新日期：2002-08-01 00:00:00

abstract：:A leukemia-associated CD9 glycoprotein antigen released into the extracellular milieu from acute lymphoblastic leukemia cells has been detected using a unique lectin-monoclonal antibody immunoassay. It has been demonstrated that the release of CD9 antigen is an active process and is associated with active cell growth....

journal_title：Leukemia & lymphoma

authors： Komada Y,Sakurai M

更新日期：1994-02-01 00:00:00

abstract：:Pulmonary marginal zone lymphoma is a rare disease arising from bronchial-associated lymphoid tissue (BALT). There is limited information on clinical presentation, natural history and treatment of this type of lymphoma. We conducted a retrospective review of patients with biopsy-proven BALT lymphoma treated at our ins...

journal_title：Leukemia & lymphoma

authors： Stefanovic A,Morgensztern D,Fong T,Lossos IS

更新日期：2008-07-01 00:00:00

abstract：:B-cell chronic lymphocytic leukemia (CLL) is a clonal B cell malignancy of morphologically mature, functionally immature B cells. B-cell CLL cells are known to be resistant to killing by anticancer and other agents. This resistance is associated with alterations in apoptosis and cell cycle regulated genes. In our earl...

journal_title：Leukemia & lymphoma

authors： Wang P,Pavletic ZS,Joshi SS

更新日期：2002-09-01 00:00:00

abstract：:Bone marrow necrosis (BMN) is a rare pathologic entity associated with a wide variety of diseases. We describe a patient with chronic myeloid leukemia on interferon treatment, who developed BMN with symptoms and signs masquerading as interferon toxicity. This is followed by a literature review of BMN in CML. ...

journal_title：Leukemia & lymphoma

authors： Chim CS,Ma SK,Lam CK

更新日期：1999-04-01 00:00:00

abstract：:The combination of mitoxantrone (MIT), etoposide (ETP), and cytarabine (Ara-C) (MEC) is a frequently used salvage therapy for acute leukemia, but has been associated with severe myelosuppression. Therefore, we investigated the miniMEC regimen with reduced doses of AraC and MIT. Thirteen ALL and 44 AML patients, all re...

journal_title：Leukemia & lymphoma

authors： Yamamoto C,Ito S,Mashima K,Umino K,Minakata D,Yamasaki R,Kawasaki Y,Sugimoto M,Nakano H,Ashizawa M,Okazuka K,Hatano K,Sato K,Oh I,Fujiwara S,Ohmine K,Suzuki T,Muroi K,Kanda Y

更新日期：2016-11-01 00:00:00

abstract：:The lung is a relatively rare site for mucosa-associated lymphoid tissue (MALT) lymphomas: we report the largest available single-center series of patients with this presentation. From August 1992 to October 2000, 12 patients with untreated primary low-grade MALT lymphoma of the lung were submitted either to chemother...

journal_title：Leukemia & lymphoma

authors： Zinzani PL,Tani M,Gabriele A,Poletti V,Stefoni V,Alinari L,Musuraca G,Bonifazi F,Pileri S,Tura S,Baccarani M

更新日期：2003-05-01 00:00:00

abstract：:Intravascular lymphoma is a rare, often fatal disease characterized by a widespread intravascular proliferation of neoplastic lymphoid cells. Dermatological and bizarre neurological manifestations usually predominate. We report a case of intravascular lymphomatosis with an exceptional clinical presentation showing spl...

journal_title：Leukemia & lymphoma

authors： Parrens M,Dubus P,Agape P,Rizcallah E,Marit G,de Mascarel A,Merlio JP

更新日期：2000-03-01 00:00:00

abstract：:The Rai and Binet staging systems, which are used as standard methods for evaluating the prognosis of chronic lymphocytic leukemia (CLL), have some restrictions in identifying patients with early-stage CLL who will progress rapidly. To solve this defect, other prognostic parameters have become important in recent year...

journal_title：Leukemia & lymphoma

authors： Hancer VS,Kose M,Diz-Kucukkaya R,Yavuz AS,Aktan M

更新日期：2011-01-01 00:00:00

abstract：:The aberrant expression of myeloid antigen CD66 on acute B-lymphoblastic leukemia (B-ALL) cells is a well-documented phenomenon. CD66a is a major subtype of the CD66 family which plays a dual role in different cancers, and the contradictory effect may depend on the isoform ratio of CD66a-4L to CD66a-4S. Although the a...

journal_title：Leukemia & lymphoma

authors： Zhao W,Zhang Y,Liu D,Zhong L,He Q,Zhao Y

更新日期：2015-01-01 00:00:00

abstract：:Abstract The aim of this study was to evaluate the prognostic importance of rituximab and radiotherapy in patients with primary mediastinal large B-cell lymphoma (PMBCL) receiving doxorubicin-containing chemotherapy. Seventy-nine patients with PMBCL received CHOP chemotherapy with (n = 39) or without rituximab (n = 40...

journal_title：Leukemia & lymphoma

authors： Xu LM,Fang H,Wang WH,Jin J,Wang SL,Liu YP,Song YW,Ren H,Zhou LQ,Li YX

更新日期：2013-08-01 00:00:00

abstract：:Plasmablastic lymphoma (PBL) is a distinct variant of diffuse large B-cell lymphoma initially described in HIV-positive patients. Several studies have reported the occurrence of PBL in HIV-negative patients, but comparative data are lacking. The goal of this study was to compare the characteristics of HIV-positive and...

journal_title：Leukemia & lymphoma

authors： Castillo JJ,Winer ES,Stachurski D,Perez K,Jabbour M,Milani C,Colvin G,Butera JN

更新日期：2010-11-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is rare among children and adolescents. The early molecular response (EMR) is an important prognostic significance for adult CML patients. This study explored the impact of EMR on the prognosis in 40 children and adolescents with CML-CP treated with imatinib (IM). Our results showed that...

journal_title：Leukemia & lymphoma

authors： Shao H,Zeng Z,Cen J,Zhang J,Bai S,Wu C,Gong Y,Wang Y,Qiu H,Chen S,Pan J

更新日期：2018-09-01 00:00:00

abstract：:B chronic lymphocytic leukemia (B-CLL) and hairy cell leukemia (HCL) cells are refractory to many of the signals which activate normal B cells but are stimulated to proliferate by tumor necrosis factor (TNF). Cell signalling by TNF is mediated in part by the induction of the transcription factor families AP-1 and NF-k...

journal_title：Leukemia & lymphoma

authors： Jabbar SA,Hoffbrand AV,Wickremasinghe RG

更新日期：1995-06-01 00:00:00

abstract：:Using a non-myeloablative stem cell trasplantation (NST) program, 25 allografts were prospectively given to 24 patients with acute myelogenous leukemia (AML) eligible for conventional allografting; 2 individuals had secondary forms of AML. The median age of the patients was 35 years, with a range of 12 to 56. All pati...

journal_title：Leukemia & lymphoma

authors： Ruiz-Argüelles GJ,Gómez-Almaguer D,David-Gomez-Rangel J,Vela-Ojeda J,Cantú-Rodríguez OG,Jaime-Pérez JC,González-Llano O,Herrera-Garza JL

更新日期：2004-06-01 00:00:00